• University of Leeds Featured PhD Programmes
  • University of Cambridge Featured PhD Programmes
  • University of Mannheim Featured PhD Programmes
  • University of Bristol Featured PhD Programmes
  • University of Glasgow Featured PhD Programmes
  • Carlos III Health Institute Featured PhD Programmes
  • University of Leeds Featured PhD Programmes
  • London School of Economics and Political Science Featured PhD Programmes
Ludwig-Maximilians-Universität Munich Featured PhD Programmes
Imperial College London Featured PhD Programmes
University of Kent Featured PhD Programmes
University of Oxford Featured PhD Programmes
University of Manchester Featured PhD Programmes

Understanding and overcoming glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.

This project is no longer listed in the FindAPhD
database and may not be available.

Click here to search the FindAPhD database
for PhD studentship opportunities
  • Full or part time
    Dr Mansour
  • Application Deadline
    No more applications being accepted
  • Funded PhD Project (European/UK Students Only)
    Funded PhD Project (European/UK Students Only)

Project Description

Glucocorticoids remain a crucial component of T-ALL chemotherapy regimens, and primary refractory disease and relapse are frequently associated with marked glucocorticoid resistance. This project will investigate mutations in the glucocorticoid receptor gene (NR3C1) in relapsed T-ALL samples, and whether low-level mutated clones are present at diagnosis and have been therefore selected by steroid-containing chemotherapy regimens. Moreover, using a combination of ChIP-seq and next generation sequencing, it will investigate the hypothesis that epigenetic alteration and/or somatic mutations occur at enhancers of pro-apoptotic genes that abrogate binding of glucocorticoid receptors to glucocorticoid-response elements. It will also study the response to glucocorticoids in IL7 receptor mutant T-ALL that is associated with hyperactivation of the JAK-STAT pathway, and whether this can be modulated with JAK inhibitors.

Elucidating the molecular mechanisms of glucocorticoid resistance in T-ALL can provide new insights into identifying those patients who have a high risk of refractory disease or relapse, informing treatment decisions and enabling the development of new therapeutic strategies to overcome such resistance.

For informal enquiries please contact Dr Marc Mansour: [email protected]

Eligibility

Physicians who are GMC-registered, meet UCL general admissions criteria, and qualify as UK/EU fee payers. These three year PhD studentships, funded by Cancer Research UK, includes a competitive clinical training salary, consumables funding, a travel allowance, and tuition fees (home/EU rate) paid in full.

Application procedure

To apply please e-mail the following pieces of information to [email protected] and provide the project number(s)* in the subject line.

1. A CV highlighting your academic achievement, clinical training, and research interest/experience, as well as stating your nationality and usual country of residence

2. A short summary (<500 words) detailing how your research interests and academic background matches the project

3. Contact details for two referees

*One application per candidate please. Although you may list more than one project per application, your short summary will need to specify how your background/interests fit each project.

Application Deadline: Applications accepted until 5.00pm 12th February 2015

Initial receipt of your application will be acknowledged. Short-listing and interviews to be done in February/March 2016. Queries about the application procedure or recruitment process should be directed to: [email protected]

How good is research at University College London in Clinical Medicine?

FTE Category A staff submitted: 449.74

Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities
Share this page:

Cookie Policy    X